The antibiotic cefazolin is an essential drug according to the World Health Organization (WHO). It is usually produced via batch manufacturing, but this multistep process is time-consuming, wasteful ...
“The global API manufacturing market is going through some major changes these days,” says Sean O’Brien, COO, Abzena. He ...
One of the main challenges came from the complex structure of cefazolin itself. Until now, no one had seemingly been able to develop a reaction method capable of synthesizing a highly purified drug by ...
The main market opportunities lie in enhancing supply chain resilience, reducing production costs and cycle times, and ...
The antibiotic cefazolin is an essential drug according to the World Health Organization (WHO). It is usually produced via batch manufacturing, but this multistep process is time-consuming, wasteful ...
Chemists designed a new photoredox catalyst that could make it easier to incorporate light-driven reactions into continuous flow manufacturing processes. The polymer catalysts could be used to coat ...
DIANT is a startup co-founded by Antonio Costa, Ph.D. and Diane Burgess, Ph.D. In 2020, DIANT licensed their core manufacturing technology from UConn and was granted a patent on the technology earlier ...
WEST LAFAYETTE, Ind. – The COVID-19 pandemic has created supply chain gaps in critical drug products, especially those needed for the most critical patients in intensive care units across the country.
Aim: To demonstrate the potential of in-line nanoparticle size measurements using the NanoFlowSizer (NFS) as a PAT method. To achieve real-time process control by establishing automated regulation of ...
Takeda is exploring a number of innovative biomanufacturing technologies because it wants to increase its ability to bring vaccines to as many people around the globe as possible [Jeffrey ...
Continuous fiber 3D printing and deposition is gaining momentum. As the number of companies using and advancing it grow, this technology will undoubtedly shape the composites industry. First, it ...